Department of Integration of Chinese and Western Medicine School of Basic Medical Sciences Peking University Beijing China.
Tasly Microcirculation Research Center Peking University Health Science Center Beijing China.
J Am Heart Assoc. 2020 Dec 15;9(24):e017876. doi: 10.1161/JAHA.120.017876. Epub 2020 Dec 5.
Background tPA (tissue-type plasminogen activator) remains the only approved drug for acute ischemic stroke, with a potentially serious adverse effect: hemorrhagic transformation. The effects of antithrombotic agents on tPA-induced hemorrhagic transformation after ischemic stroke are not clearly defined. We performed a systematic review and meta-analysis in preclinical studies aiming to evaluate the efficacy of antithrombotic agents on tPA-induced hemorrhagic transformation after ischemic stroke. Methods and Results We conducted a systematic review and meta-analysis of studies testing antithrombotic agents in animal models of tPA-induced hemorrhagic transformation. The pooled effects were calculated using random-effects models, and heterogeneity was explored through meta-regression and subgroup analyses. Publication bias was assessed using trim and fill method and the Egger test. The efficacy of 18 distinct interventions was described in 22 publications. The pooled data showed a significant improvement in cerebral hemorrhage, infarct size, and neurobehavioral outcome in treated compared with control animals (standardized mean difference, 0.45 [95% CI, 0.11-0.78]; standardized mean difference, 1.18 [95% CI, 0.73-1.64]; and standardized mean difference, 0.91 [95% CI, 0.49-1.32], respectively). Subgroup analysis indicated that quality score, random allocation, control of temperature, anesthetic used, stroke model used, route of drug delivery, time of drug administration, and time of assessment were significant factors that influenced the effects of interventions. Conclusions Administration with antiplatelet agents revealed statistically significant improvement in all the outcomes. Anticoagulant agents showed significant effects in infarct size and neurobehavioral score, but fibrinolytic agents did not show any significant improvement in all the outcomes. The conclusions should be interpreted cautiously given the heterogeneity and publication bias identified in this analysis.
组织型纤溶酶原激活剂(tissue-type plasminogen activator,tPA)仍然是急性缺血性脑卒中唯一批准的药物,但有潜在的严重不良反应:出血性转化。抗血栓药物对缺血性脑卒中后 tPA 诱导的出血性转化的影响尚未明确。我们进行了一项系统评价和荟萃分析,旨在评估抗血栓药物对缺血性脑卒中后 tPA 诱导的出血性转化的疗效。
我们对动物模型中测试抗血栓药物治疗 tPA 诱导的出血性转化的研究进行了系统评价和荟萃分析。使用随机效应模型计算汇总效应,并通过meta 回归和亚组分析探索异质性。使用修剪和填充法和 Egger 检验评估发表偏倚。22 篇文献描述了 18 种不同干预措施的疗效。汇总数据显示,与对照组相比,治疗组的脑出血、梗死面积和神经行为学结果均有显著改善(标准化均数差,0.45 [95%置信区间,0.11-0.78];标准化均数差,1.18 [95%置信区间,0.73-1.64];和标准化均数差,0.91 [95%置信区间,0.49-1.32])。亚组分析表明,质量评分、随机分组、体温控制、使用的麻醉剂、使用的脑卒中模型、药物给药途径、药物给药时间和评估时间是影响干预效果的重要因素。
抗血小板药物治疗在所有结局中均显示出统计学意义上的显著改善。抗凝药物在梗死面积和神经行为评分方面显示出显著效果,但溶栓药物在所有结局中均未显示出任何显著改善。鉴于本分析中发现的异质性和发表偏倚,应谨慎解释这些结论。